Legend Biotech Corp (LEGN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Legend Biotech Corp $2.65, price $18.57, upside -85.7%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Legend Biotech Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range $16.65 – $76.50 · fair‑value band $1.75 – $3.31 · the $18.57 price screens above the $2.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Legend Biotech in your weekly email
Every Wednesday you see whether Legend Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Show more
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Stock analysis
Legend Biotech Corp (LEGN) currently trades at $18.57, while our model-based Fair Value estimate is $2.65, 85.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.75 (bear) to $3.31 (bull), the price of $18.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Legend Biotech Corp reported revenue of $1.0B in FY2025 versus $68.8M in FY2021, a compound +96.6%/yr. Reported net income was −$297M in FY2025.
Key figures
Market cap $3.6B · P/S ratio 2.92 · EPS (TTM) $−0.5000 · Net margin −28.8% · Return on equity −8.1% · Return on assets (EBIT) −23.8% · Operating margin 14.9% · Revenue (TTM) $1.3B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −86%, LEGN screens richer than that median.
Fair Value models
Bear $1.75Fair Value $2.65Bull $3.31
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+64.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+106.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+68.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.3%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−417.8% (2020) → −13.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Below median
Fair Value upside−86.3% · Bottom 25%
Profitability
Return on assets−1.9% · Above median
Net margin (TTM)−7.2% · Below median
Operating margin (TTM)14.9% · Top 25%
Growth and dividend
Revenue growth51.9% · Top 25%
Balance sheet
Debt / equity0.30× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B3.74× · Priciest 25%
P/S (TTM)2.95× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)85· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Legend Biotech Corp (LEGN) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $2.65 versus a price of $18.57, about −86% upside (overvalued).
What is the fair value of LEGN?
Our model-based fair value for Legend Biotech Corp is $2.65 (as of Oct 2, 2026), built from audited fundamentals. The current price: $18.57.
What is the quality score of LEGN?
Legend Biotech Corp has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Legend Biotech Corp (LEGN)?
Our model-based price target is the fair value of $2.65 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario $1.75, optimistic scenario $3.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Legend Biotech Corp stock forecast for 2026?
Our models put fair value at $2.65, about −86% upside versus a price of $18.57 (overvalued). Cautious scenario $1.75, optimistic scenario $3.31. The calculation is refreshed regularly with new filings.
What is the revenue of Legend Biotech Corp (LEGN)?
Legend Biotech Corp reported trailing-twelve-month revenue of about $1.3B (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Legend Biotech Corp (LEGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Legend Biotech Corp it is $2.65 per share (as of Oct 2, 2026), against a price of $18.57. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Legend Biotech Corp stock overvalued or undervalued in 2026?
As of Oct 2, 2026, LEGN trades above its calculated fair value: price $18.57, fair value $2.65, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LEGN?
No. The price is what the market pays today ($18.57); the fair value is what the company's own numbers justify ($2.65). For Legend Biotech Corp the two are $15.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is Legend Biotech Corp worth?
The market values Legend Biotech Corp at about $3.6B (market capitalisation, as of Oct 2, 2026). Per share that is $18.57; our models calculate a fair value of $2.65 per share.
What do the bullish and bearish scenarios say about LEGN?
Our models span a range for Legend Biotech Corp: cautious scenario $1.75, base $2.65, optimistic $3.31 per share (as of Oct 2, 2026, price $18.57). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Legend Biotech Corp (LEGN)?
Balance-sheet figures for Legend Biotech Corp (as of Oct 2, 2026): return on equity −8.1%, debt of 0.30 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is LEGN from its 52-week high?
Legend Biotech Corp trades at $18.57, about 49% below its 52-week high of $36.28 and 12% above the low of $16.65 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.65 is for.
Which stocks are comparable to Legend Biotech Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Legend Biotech Corp stock attractive at the current price?
The data as of Oct 2, 2026: price $18.57, calculated fair value $2.65 (−86%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LEGN calculated?
We run Legend Biotech Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.65, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Legend Biotech Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Legend Biotech Corp (LEGN)?
The closing price on Oct 2, 2026 was $18.57. Our model-based fair value is $2.65, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Legend Biotech Corp right now?
The price sits above even our optimistic bull case ($3.31). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.75 to $3.31) leaves room in how you read the outcome.
Key figures of Legend Biotech Corp
How large is the market capitalisation of Legend Biotech Corp (LEGN)?
The market capitalisation of Legend Biotech Corp is $3.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Legend Biotech Corp (LEGN)?
The price-to-sales ratio of Legend Biotech Corp is 2.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Legend Biotech Corp (LEGN)?
Earnings per share at Legend Biotech Corp are $−0.5000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Legend Biotech Corp (LEGN)?
The net margin of Legend Biotech Corp is −28.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Legend Biotech Corp (LEGN)?
The return on equity (ROE) of Legend Biotech Corp is −8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Legend Biotech Corp (LEGN)?
On an EBIT basis the return on assets of Legend Biotech Corp is −23.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Legend Biotech Corp (LEGN)?
The operating margin of Legend Biotech Corp is 14.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Legend Biotech Corp (LEGN)?
Revenue at Legend Biotech Corp is growing +51.9% versus a year earlier (3y avg +106%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Legend Biotech Corp (LEGN) generate?
The free cash flow of Legend Biotech Corp is −$168M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Legend Biotech Corp (LEGN) hold?
Legend Biotech Corp holds more cash than debt, $488M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Legend Biotech Corp in the live analysis
One click puts Legend Biotech Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 2, 2026